(AOF) – Nicox announces that its resources are focused on the clinical development of its main program, NCX 470, against glaucoma. The biotech specializing in ophthalmology is counting on obtaining the main results of the Denali phase 3 clinical study on this product in patients with open-angle glaucoma or ocular hypertension in the second half of 2025. Its strategic objective is to secure funding to support the clinical development of NCX 470.
“We are reducing costs and the size of the organization” and “focusing on securing financing to secure the debt restructuring and provide innovative treatment with the NCX 470” said Gavin Spencer, new director general of Nicox.
“We are holding discussions with potential partners for the NCX 470 in the United States and other territories, beyond those already subject to licensing agreements, and keeping them informed of the progress of the program .”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
